A randomized, double-blind, placebo-controlled, multicenter dose ranging study of ALX-0171 in infants and young children hospitalized for respiratory syncytial virus lower respiratory tract infection
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs ALX 0171 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms Respire
- Sponsors Ablynx
- 11 Jan 2017 According to an Ablynx media release, top-line results from this trial are expected in the second half of 2018.
- 11 Jan 2017 According to an Ablynx media release, the first patient has been dosed in this trial.
- 11 Jan 2017 According to an Ablynx media release, status changed from not yet recruiting to recruiting.